Introduction
============

The difference in energy production between cancer cells and normal cells is considered to be one of the available targets for the treatment of cancer ([@b1-ol-0-0-6195]). Unlike normal cells, cancer cells obtain energy mostly via glycolysis, while mitochondrial oxidative phosphorylation is reduced ([@b2-ol-0-0-6195]). As tumor cells actively proliferate, they require a constant energy supply and it has been postulated that they switch to aerobic glycolysis characterized by rapid ATP production, which is known as the Warburg effect ([@b2-ol-0-0-6195]). It is hypothesized that the purpose of the Warburg effect is to avoid the excessive generation of reactive oxygen species (ROS) during oxidative phosphorylation in mitochondria, and the subsequent oxidative stress that causes cell damage ([@b1-ol-0-0-6195],[@b3-ol-0-0-6195]). The differences in the energy metabolism between tumor and normal cells have previously been exploited in cancer treatment, and the efficacy of a number of currently used chemotherapeutic agents, including methotrexate, depends on ROS production ([@b3-ol-0-0-6195]).

Excessive oxidative stress can be generated by forcing cancer cells to produce energy via mitochondrial oxidation, which is expected to cause anticancer effects without injury to benign cells, as for the latter it is a normal metabolic process ([@b4-ol-0-0-6195]). A previous study indicated that ketone bodies and medium-chain fatty acids (MCFAs) may be used as a tool to induce cancer cells to switch between glycolysis and oxidative phosphorylation for energy production, indicating that ketogenic and MCFA-enriched diets may be beneficial in cancer therapy ([@b5-ol-0-0-6195]).

In mitochondria, fatty acids are metabolized to acetyl-CoA via β-oxidation, which can be diverted to the formation of ketone bodies under the conditions of glucose starvation ([@b5-ol-0-0-6195],[@b6-ol-0-0-6195]). β-hydroxybutyric acid (β-HBA, also termed 3-HBA) is one of the three ketone bodies generated from fatty acids; it has been revealed that 3-HBA can be used for energy production in mitochondria through the tricarboxylic acid cycle, where it is converted into acetoacetic acid and then to acetyl-CoA ([@b7-ol-0-0-6195],[@b8-ol-0-0-6195]). Ketogenic diets rich in medium-chain triglycerides demonstrated inhibitory effects on cancer growth, and it was observed that prostate cancer cells had lower ability to utilize dietary fatty acids compared with normal prostate cells, indicating possible therapeutic potential. Lauric acid (LAA) is an MCFA with an aliphatic tail of 12 carbons, which, contrary to long-chain fatty acids (LCFAs), can be transported to the mitochondrial intermembrane space directly without the carnitine shuttle ([@b9-ol-0-0-6195]). Therefore, LAA is utilized through β-oxidation with higher efficacy than LCFAs ([@b10-ol-0-0-6195]). The present study examined the effect of 3-HBA and LAA on cancer cell proliferation, oxidative stress and stemness, with the aim of providing mechanistic insights into a potentially therapeutic effect of ketogenic diets for patients with cancer.

Materials and methods
=====================

### Cell culture and treatment

The mouse CT26 colon cancer cell line was provided by Professor I. J. Fidler (MD Anderson Cancer Center, Texas University, Austin, TX, USA). Cells were cultured in Dulbecco\'s modified Eagle\'s medium containing high glucose (450 mg/dl), low glucose (100 mg/dl) or no glucose (Wako Pure Chemical Industries, Ltd., Osaka, Japan), and supplemented with 10% fetal bovine serum (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 37°C in 5% CO2. Cells were treated with 3-HBA (1 mM; Sigma-Aldrich; Merck KGaA) and/or LAA (1.5 mM; Wako Pure Chemical Industries, Ltd.) for 24 h at 37°C, and analyzed for viability using a tetrazolium dye (MTT; Sigma-Aldrich; Merck KGaA) assay, as previously described ([@b11-ol-0-0-6195]). 3-HBA was solubilized using PBS at room temperature. LAA was solubilized in 60°C PBS and kept at 37°C until use. All procedures were performed in accordance with the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government, which was approved by the Ethics Committee of Nara Medical University (approval no., 937-1).

Mitochondrial volume was assessed by staining mitochondria with MitoGreen by adding MitoGreen-dimethyl sulfoxide solution (200 µM) to cultured cells (50 nM at working concentration) for 1 h at 37°C (Takara Bio, Inc., Otsu, Japan). Cell images were captured under a fluorescence microscope equipped with a camera (Leica Microsystems, Inc., Buffalo Grove, IL, USA), and fluorescence was evaluated in the images using Photoshop Image Analyzer (CS2; version 9.0.2; Adobe Systems, Inc., San Jose, CA, USA). Alkaline phosphatase (ALP) activity was determined using a commercial kit according to the manufacturer\'s protocol (LabAssay ALP; catalog no., 291-58601; Wako Pure Chemical Industries, Ltd.). GSSG (by High-Throughput Glutathione Assay kit) and 4-HNE (by OxiSelect HNE Adduct ELISA Kit) were measured in cell lysates using ELISA kits (R&D Systems, Inc., Minneapolis, MN, USA), according to the manufacturer\'s protocol. Whole-cell lysates were prepared in 0.1% Nonidet 40-containing lysis buffer (Wako Pure Chemical Industries, Ltd.) as previously described ([@b12-ol-0-0-6195]).

### Reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA was extracted using an RNeasy kit from 1×10^7^ CT26 cells according to the manufacturer\'s protocol (Qiagen, Inc., Valencia, CA, USA). cDNA was synthesized from 0.5 µg RNA using ReverTra Ace RT-qPCR kit (Toyobo Co., Ltd., Osaka, Japan) and used as a template for q-PCR. The thermocycler settings were 30 cycles of 96°C for 30 sec, 64°C for 30 sec and 72°C for 30 sec, followed by 72°C for 10 min. The expression of monocarboxylic acid transporter (Mct)1, Mct5, succinyl-CoA transferase (Scot), NADH dehydrogenase (ubiquinone) 1 α subcomplex, 9 (Ndufa9), succinate dehydrogenase complex, subunit A, flavoprotein (Sdha), Ubiquinol cytochrome *c* reductase core protein 2 (Uqcrc2), cytochrome *c* oxidase II (mtCo2), ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F2 (Atp5j2), F1 ATPase inhibitor (If1), PTEN-induced putative kinase 1 (Pink1) and GAPDH were quantified. Primers were synthesized by Sigma Genosys (Ishikari, Japan); the sequences are presented in [Table I](#tI-ol-0-0-6195){ref-type="table"}. PCR products were separated by electrophoresis in 2% agarose, and then stained with ethidium bromide (Wako Pure Chemical Industries, Ltd.) for 30 min at room temperature. The level present in untreated cells grown under 450 mg/dl glucose was set as 10%. For Pink1, semi-quantitative analysis, the level present in untreated cells grown under glucose free-conditions was set as 100%. Semi-quantitation was performed on captured gel images from an EPSON image scanner (Tokyo, Japan). The captured images were analyzed by densitometry with NIH Image (version 1.63; National Institute of Mental Health, Bethesda, MD, USA). Each experiment was performed in triplicate.

### Statistical analysis

Statistical significance was calculated using two-tailed Fisher\'s exact, χ^2^ and unpaired Student t-tests using InStat software (version 3.0; GraphPad Software, Inc., La Jolla, CA, USA). Data are expressed as the mean ± standard deviation of three independent experiments. P\<0.05 (two-sided) was considered to indicate a statistically significant difference.

Results
=======

### Expression of fatty acid transporters and ketone body metabolism-associated genes in CT26 cells

First, the mRNA expression of transporters for short-chain fatty acids (SCFAs) and MCFAs in CT26 cells treated with 3-HBA and LAA was determined ([Fig. 1](#f1-ol-0-0-6195){ref-type="fig"}). 3-HBA has an aliphatic chain similar to that of SCFAs and is transported by monocarboxylate transporters (*Mct*s) 1--4, while LAA is an MCFA transported by *Mct*s 5--7 ([@b13-ol-0-0-6195],[@b14-ol-0-0-6195]). The results indicated that CT26 cells expressed *Mct1* and *Mct5*. CT26 cells also expressed 3-oxoacid CoA transferase (SCOT), a key enzyme involved in metabolizing 3-HBA to acetoacetate ([@b15-ol-0-0-6195],[@b16-ol-0-0-6195]); however, mRNA levels were low and not significantly affected by 3-HBA or LAA treatment ([Fig. 1](#f1-ol-0-0-6195){ref-type="fig"}).

### Effect of 3-HBA and LAA on CT26 cell proliferation, stemness and oxidative stress

The effect of 3-HBA and LAA on CT26 cells grown in the presence of various glucose concentrations was subsequently examined ([Fig. 2](#f2-ol-0-0-6195){ref-type="fig"}). The results revealed that the proliferation of CT26 cells was correspondingly increased with the glucose concentration, but the addition of 3-HBA or LAA into the medium inhibited cell proliferation at each glucose concentration ([Fig. 2A](#f2-ol-0-0-6195){ref-type="fig"}). The suppressive effect of LAA on cell growth was markedly high. Lipid peroxidation assessed based on 4-HNE levels was not significantly different in any glucose concentration. By contrast, 4-HNE levels were upregulated with 3-HBA, and more so with LAA ([Fig. 2B](#f2-ol-0-0-6195){ref-type="fig"}). Cancer cell stemness was evaluated via ALP activity ([@b17-ol-0-0-6195]), which was inversely associated with the glucose concentration ([Fig. 2C](#f2-ol-0-0-6195){ref-type="fig"}). The 3-HBA increased ALP activity in glucose-free, but not in glucose-supplemented, medium. By contrast, LAA induced ALP activity under all conditions. Lactate concentration in the medium increased with the glucose concentration, but was decreased following the administration of 3-HBA and LAA ([Fig. 2D](#f2-ol-0-0-6195){ref-type="fig"}).

### Effect of 3-HBA and LAA on mitochondrial volume in CT26 cells

The effect of 3-HBA and LAA on mitochondrial volume in CT26 cells was then examined, and it was revealed that it inversely associated with the glucose concentration in the cells treated with 3-HBA or LAA ([Fig. 3](#f3-ol-0-0-6195){ref-type="fig"}). The 3-HBA increased mitochondrial volume at glucose concentrations of 0 and 100 mg/dl ([Fig. 3A and B](#f3-ol-0-0-6195){ref-type="fig"}). By contrast, LAA decreased mitochondrial volume at glucose concentrations of 100 and 450 mg/dl ([Fig. 3D-H](#f3-ol-0-0-6195){ref-type="fig"}).

### Effect of concurrent LAA and 3-HBA treatment on CT26 cell proliferation, stemness and oxidative stress

The concurrent treatment with LAA and 3-HBA inhibited cell proliferation and ALP activity in CT26 cells ([Fig. 4A and B](#f4-ol-0-0-6195){ref-type="fig"}) and significantly increased GSSG ([Fig. 4C](#f4-ol-0-0-6195){ref-type="fig"}), whilst also decreasing lactate ([Fig. 4D](#f4-ol-0-0-6195){ref-type="fig"}) under all glucose concentrations (P\<0.05). LAA and 3-HBA decreased mitochondrial volume at all glucose concentrations, compared with that at 100 mg/ml glucose alone; however, higher glucose concentrations induced a more pronounced decrease in mitochondrial volume ([Fig. 4E-G](#f4-ol-0-0-6195){ref-type="fig"}).

### Effect of 3-HBA and LAA on the expression of enzyme complexes involved in oxidative phosphorylation

The increase in oxidative stress and alterations to mitochondrial volume indicated that 3-HBA and LAA may affect oxidative phosphorylation in mitochondria. Therefore, the mRNA expression of enzymatic complexes in the oxidative phosphorylation system was examined by RT-PCR ([Fig. 5](#f5-ol-0-0-6195){ref-type="fig"}). Semi-quantitative analysis of the results revealed that the expression of electron transfer system complexes in the mitochondria was altered by glucose concentration, 3-HBA and/or LAA treatments in comparison with those in glucose-free medium ([Fig. 5B](#f5-ol-0-0-6195){ref-type="fig"}). In detail, treatment with 3-HBA decreased the levels of complex V under glucose-free and normal (100 mg/dl) glucose concentrations, whereas LAA administered alone downregulated the expression of all complexes in glucose-free conditions, and when in combination with 3-HBA reduced the expression of complexes under glucose-free as well as high-glucose conditions ([Fig. 5B](#f5-ol-0-0-6195){ref-type="fig"}).

Furthermore, gene expression of the mitochondrial volume-associated factors inhibitor factor 1 (*If1*) and protein phosphatase and tensin homolog-induced kinase 1 (*Pink1*) was examined ([Fig. 5C and D](#f5-ol-0-0-6195){ref-type="fig"}). In the untreated control cells, IF1 expression was not detected, irrespective of the glucose concentration; however, 3-HBA and LAA upregulated *If1* mRNA to detectable levels in each condition, and the concurrent treatment of 3-HBA with LAA markedly increased IF1 expression. *Pink1* expression was constitutive in control cells, irrespective of the glucose concentration. The 3-HBA treatment did not significantly affect *Pink1* levels; however, they were decreased by treatment with LAA and with 3-HBA + LAA, particularly in cells cultured at high glucose concentrations.

Discussion
==========

In the present study, it was identified that the addition of 3-HBA or LAA inhibited the growth of CT26 colon cancer cells. In normal tissues, 3-HBA and LAA are utilized for metabolic processes, including energy production and lipogenesis, particularly in hypoglycemic conditions ([@b13-ol-0-0-6195]--[@b16-ol-0-0-6195]). The MCT isoforms 1--4 are transporters of SCFAs and monocarboxylates, including 3-HBA ([@b13-ol-0-0-6195]). It has been demonstrated that, in a hypermetabolic state, MCTs 1--4 are upregulated in the brain in order to transport ketone bodies and lactate ([@b14-ol-0-0-6195]). MCFAs, however, are transported by MCTs 5--7 and, in contrast to LCFAs, do not require the carnitine shuttle to be imported into mitochondria ([@b6-ol-0-0-6195],[@b15-ol-0-0-6195]).

Cancer cells can utilize ketone bodies or LAA ([@b16-ol-0-0-6195],[@b18-ol-0-0-6195]). It was previously revealed that gastric cancer cells could continue growing in glucose-free medium supplemented with ketone bodies ([@b16-ol-0-0-6195]). Utilization of ketone bodies in gastric cancer cells is regulated by the expression of SCOT, a key enzyme involved in ketone body metabolism ([@b16-ol-0-0-6195]), and it was reported that neuroblastoma cells were unable to use ketone bodies as an energy source, due to decreased SCOT expression ([@b18-ol-0-0-6195]).

Therefore, the present study examined the expression of MCT1, MCT5 and SCOT, which enable the utilization of 3-HBA and LAA in colon cancer cells. However, the levels of SCOT expression were low, which is consistent with the lower SCOT levels in cancer cells compared with in cancer-associated fibroblasts observed in colorectal cancer ([@b19-ol-0-0-6195]). By contrast, the carnitine shuttle enzyme carnitine palmitoyltransferase 1A (CPT1), which is important for fatty acid transport into mitochondria, was expressed at high levels in CT26 cells ([@b20-ol-0-0-6195]). The experimental concentration of 3-HBA (1 mM) in the present study was equivalent to serum levels of ketone bodies present in individuals fed a carbohydrate-limited diet ([@b21-ol-0-0-6195]). The experimental concentration of LAA was also equivalent to the serum fatty acid concentration ([@b22-ol-0-0-6195]). Thus, LAA may provide higher mitochondria-activating effect on energy metabolism compared with 3-HBA.

In normal tissues, SCFAs and MCFAs inhibit glycolysis and stimulate lipogenesis or gluconeogenesis ([@b15-ol-0-0-6195]). SCFAs and MCFAs exhibit no or weak protonophoric and lytic activities in mitochondria, and decrease the efficacy of oxidative ATP synthesis ([@b15-ol-0-0-6195]). However, SCFAs and MCFAs also increase the mitochondrial respiratory capacity in normal physiological and inflammatory conditions ([@b23-ol-0-0-6195]). MCFAs also stimulate fatty acid oxidization and energy production in mitochondria in type II skeletal muscle ([@b24-ol-0-0-6195]). In cancer, SCOT, the rate-limiting enzyme for the production of ketone bodies, and CPT1, the carnitine shuttle protein, is associated with the cell metastatic potential, as evidenced by their increased expression in the highly metastatic SW620 cells, as compared with in the low metastatic parental SW480 cells ([@b25-ol-0-0-6195]). In the present study, 3-HBA and LAA decreased lactate fermentation, particularly under glucose starvation, indicating that 3-HBA and LAA switch the energy production pathway from glycolysis and lactate fermentation to oxidative phosphorylation.

Oxidative phosphorylation is considered a major intracellular source of oxidative stress ([@b26-ol-0-0-6195]). Activation of mitochondria is followed by oxidative stress, which may induce cell and tissue damage ([@b26-ol-0-0-6195]). Hydrogen peroxide release is increased in mitochondria during the oxidation of MCFAs supplied in the form of carnitine esters ([@b27-ol-0-0-6195]). Consistent with these findings, the present results indicated that 3-HBA and LAA increased oxidative stress in parallel with the enhancement of energy production in mitochondria.

The imbalance in the complexes of the electron transport chain (ETC), characteristic of aged mitochondria, induces the generation of ROS ([@b28-ol-0-0-6195]). Notably, 3-HBA and LAA caused the imbalance of ETC complexes in addition to the downregulation of PINK1, which is a major factor in PINK1-Parkin-mediated mitophagy ([@b29-ol-0-0-6195]). The decrease in PINK1 suggests retardation of the mitochondrial turnover, which may promote the imbalance of ETC complexes and result in ROS production, which in turn may damage the mitochondria. The present data suggested that 3-HBA- and LAA-associated oxidative stress is associated with the decrease in mitochondrial volume. The depletion of proteins involved in autophagy leads to mitochondrial dysfunction, decreased ATP production and increased ROS release, ultimately resulting in the apoptosis of mesenchymal stem cells ([@b30-ol-0-0-6195]).

Thus, the present data suggested that ketone bodies and MCFAs may exert anticancer effects via the deviation of energy metabolism from glycolysis-lactate fermentation to oxidative phosphorylation. Additional studies are required to compare the responses to ketone bodies and MCFAs in normal and cancer tissues, in order to verify the therapeutic effect of LAA and 3-HBA dietary supplementation for patients with cancer.

The authors thank Ms. Tomomi Masutani for expert assistance with the preparation of this manuscript. The present study was supported by Mext Kakenhi (grant nos. 14478268 and 16675788).

![Expression of fatty acid transporters and a ketone body-metabolizing enzyme in CT26 cells. Expression of the monocarboxylate transporters MCT1 and MCT5 and SCOT in CT26 cells treated with 3-HBA (1 mM) or LAA (1.5 mM) was examined by reverse transcription-polymerase chain reaction. GAPDH, loading control. SCOT, 3-oxoacid CoA transferase; MCT, monocarboxylate transporter; 3-HBA, 3-hydroxybutyric acid; LAA, lauric acid.](ol-14-01-0673-g00){#f1-ol-0-0-6195}

![Effect of 3-HBA and LAA in CT26 cells. (A) Cell growth, (B) oxidative stress (4-HNE), (C) cell stemness (ALP) and (D) non-mitochondrial energy production (lactate) were examined in CT26 cells grown under various concentrations of glucose and treated with 3-HBA or LAA. The data are expressed as the mean ± standard deviation of three independent experiments. 3-HBA, 3-hydroxybutyric acid; LAA, lauric acid; ALP, alkaline phosphatase; Glc, glucose; 4-HNE, 4-hydroxynonenal.](ol-14-01-0673-g01){#f2-ol-0-0-6195}

![Effect of 3-HBA or LAA on mitochondrial volume in CT26 cells. Mitochondrial volume was examined in CT26 cells treated with 3-HBA (A-C) or LAA (D-F) using MitoGreen. Each panel is representative of the following treatments: (A) Glucose-free with 1 mM 3-HBA; (B) 100 mg/dl glucose with 1 mM 3-HBA; (C) 450 mg/dl glucose with 1 mM 3-HBA; (D) Glucose-free with 1.5 mM LAA; (E) 100 mg/dl glucose with 1.5 mM LAA; (F) 450 mg/dl glucose with 1.5 mM LAA; (G) 100 mg/dl glucose without LAA (control). (H) Fluorescence intensity was quantified relative to the control, which was set as 100%. The data are expressed as the mean ± standard deviation of three independent experiments. 3-HBA, 3-hydroxybutyric acid; LAA, lauric acid; Glc, glucose.](ol-14-01-0673-g02){#f3-ol-0-0-6195}

![Effect of concurrent treatment with LAA and 3-HBA in CT26 cells. (A) Cell proliferation, (B) stemness (ALP), (C) oxidative stress (GSSG) and (D) non-mitochondrial energy production (lactate). The data are expressed as the mean ± SD of three independent experiments. (E and F) Mitochondrial volume was examined in CT26 cells treated with glucose (100 mg/dl as a control) (E) or LAA (1.5 mM) and 3-HBA (1 mM) (F) using MitoGreen. (G) Fluorescence intensity was quantified as relative to the control set as 100%. The data are expressed as the mean ± SD of three independent experiments. SD, standard deviation. 3-HBA, 3-hydroxybutyric acid; LAA, lauric acid; Glc, glucose; ALP, alkaline phosphatase; GSSG, glutathione disulfide.](ol-14-01-0673-g03){#f4-ol-0-0-6195}

![Expression of mitochondrial genes in CT26 cells treated with 3-HBA and/or LAA. (A) Expression of the *Ndufa9* (complex I), *Sdha* (complex II), *Uqcrc2* (complex III), *mtCo2* (complex IV) and *Atp5j2* (complex V) genes were examined by RT-PCR. GAPDH, loading control. (B) Semi-quantitative analysis of the expression of mitochondrial complex enzymes. (C) Expression of the *If1*- and *Pink1*-encoding genes was examined by RT-PCR. GAPDH, loading control. (D) Semi-quantitative analysis of IF1 expression. The level present in untreated cells grown under 450 mg/dl glucose was set as 10%. (E) Semi-quantitative analysis of Pink1 expression. The level present in untreated cells grown under glucose free-conditions was set as 100%. The data are expressed as the mean ± standard deviation of three independent experiments. RT-PCR, reverse transcription-polymerase chain reaction; 3-HBA, 3-hydroxybutyric acid; LAA, lauric acid; If1, F1 ATPase inhibitor; Pink1, protein phosphatase and tensin homolog-induced kinase 1; Sdha, succinate dehydrogenase complex, subunit; Uqcrc2, ubiquinol cytochrome *c* reductase core protein 2; mtCo2, cytochrome *c* oxidase II; Ndufa9, NADH dehydrogenase (ubiquinone) 1 α subcomplex, 9; Atp5j2, ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F2.](ol-14-01-0673-g04){#f5-ol-0-0-6195}

###### 

List of primer sets for reverse transcription-polymerase chain reaction.

  Gene name                                                               Gene symbol   Figure abbreviation   Accession no.    Upper primer (5′ to 3′)   Lower primer (5′ to 3′)
  ----------------------------------------------------------------------- ------------- --------------------- ---------------- ------------------------- -------------------------
  ATPase inhibitor                                                        *IF1*         If1                   AF002718.1       tctggggtatgaaggtcctg      tcgaatggtggtcaatctca
  Succinyl CoA transferase                                                *Scot*        Scot                  AB085609.1       ctgccttctacaccagcaca      catgctttcaccagagcaaa
  Solute carrier family 16 (monocarboxylic acid transporters), member 1   *Slc16a1*     Mct1                  NM_009196.4      gctggaggtcctatcagcag      agttgaaagcaagcccaaga
  Solute carrier family 16 (monocarboxylic acid transporters), member 5   *Slc16a5*     Mct5                  NM_001080934.1   cctgtccatgtgtggagttg      cccacacccaggataagaga
  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9                   *Ndufa9*      Ndufa9, Com I         NM_009933.4      acacagacctggtggagacc      ggatgggcttggagtaatca
  Succinate dehydrogenase complex, subunit A, flavoprotein                *Sdha*        Sdha, Com II          NM_025358.3      actgtgtttggggctacagg      gattgatgaccacgttgctg
  Ubiquinol cytochrome *c* reductase core protein 2                       *Uqcrc2*      Uqcrc2, Com III       NM_025899.2      gtcagagggcttcctgagtg      actcgtcgagaaaaggcgta
  Cytochrome c oxidase II                                                 *mtCo2*       mtCo2, Com IV         AB284309.1       ggcagaacgactcggttatc      acgaaatcaacaaccccgta
  ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F2     *Atp5j2*      Atp5j2, Com V         NM_020582.2      ccttccaccgggatttttat      aatttggcagctatgggaga
  PTEN induced putative kinase 1                                          *Pink1*       Pink1                 NM_026880.2      cccacaccctaacatcatcc      actgggagtctgctcctcaa
  Glyceraldehyde-3-phosphate dehydrogenase                                *Gapdh*       Gapdh                 NM_001289726.1   aactttggcattgtggaagg      acacattgggggtaggaaca
